<DOC>
	<DOC>NCT00803660</DOC>
	<brief_summary>Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP&lt;130/80 mmHg. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP&lt;130/80 mmHg by treatment groups. To observe the proportion of patients achieving a therapeutic glycemic response defined as HbA1c=&lt;7%. To observe the proportion of patients achieving fasting plasma glucose&lt;110 mg%. To identify factors for not achieving BP&lt;130/80 mmHg. To describe percentage of patients with positive proteinuria (including microalbuminuria) by treatment groups .</brief_summary>
	<brief_title>Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Provision of written informed consent Patient was diagnosed with type 2 diabetes Patient is on antihypertensive treatments for at least 3 months, with the same regimen for a minimum of 4 weeks prior to survey Patients are critically ill, had mental health problems or difficulty in communication Patients who are unwilling or unable to provide informed consent Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>hypertension</keyword>
	<keyword>BP</keyword>
	<keyword>diabetes</keyword>
	<keyword>anti-hypertensive treatment</keyword>
	<keyword>ACE-I</keyword>
	<keyword>ARB</keyword>
</DOC>